<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE- spironolactone and hydrochlorothiazide tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1><span class="Bold"></span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="box"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First">Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a>). Spironolactone and hydrochlorothiazide should be used only in those conditions described under <a href="#i4i_indications_id_f54156e2-c125-4706-aeec-a5d001c5ff87">INDICATIONS AND USAGE</a>. Unnecessary use of this drug should be avoided.</p>
<p>Fixed-dose combination drugs are not indicated for initial therapy of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is not static but must be reevaluated as conditions in each patient warrant.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_fc692bd0-14cc-490a-b253-c897cf8eb0f9"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each tablet of spironolactone and hydrochlorothiazide contains 25 mg of spironolactone, USP and 25 mg of hydrochlorothiazide, USP. Spironolactone, an aldosterone antagonist, is 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate and has the following structural formula, molecular formula and molecular weight:</p>
<div class="Figure">
<a name="id297"></a><img alt="Spironolactone Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66134130-5718-483b-a076-36ecdb0add34&amp;name=25869be1-c481-4e3a-9fee-1505c41b39d1-01.jpg">
</div>
<p>C<span class="Sub">24</span>H<span class="Sub">32</span>O<span class="Sub">4</span>S<br>M.W. = 416.59</p>
<p>Spironolactone is practically insoluble in water, soluble in alcohol and freely soluble in benzene and in chloroform.</p>
<p>Hydrochlorothiazide, a diuretic and antihypertensive, is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide and has the following structural formula, molecular formula and molecular weight:</p>
<div class="Figure">
<a name="id305"></a><img alt="Hydrochlorothiazide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66134130-5718-483b-a076-36ecdb0add34&amp;name=25869be1-c481-4e3a-9fee-1505c41b39d1-02.jpg">
</div>
<p>C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span><br>M.W. = 297.75</p>
<p>Hydrochlorothiazide is slightly soluble in water and freely soluble in sodium hydroxide solution.</p>
<p>Each tablet for oral administration contains 25 mg of spironolactone and 25 mg of hydrochlorothiazide and the following inactive ingredients: colloidal silicon dioxide, corn starch, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, menthol, microcrystalline cellulose, peppermint oil, sodium lauryl sulfate and sodium starch glycolate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_d1089fc4-82c7-4a03-947c-15a51cc80073"></a><a name="section-2"></a><p></p>
<h1>ACTIONS/CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_d30ac74b-9854-49d6-8683-81376e5aefd6"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Spironolactone and hydrochlorothiazide is a combination of two diuretic agents with different but complementary mechanisms and sites of action, thereby providing additive diuretic and antihypertensive effects. Additionally, the spironolactone component helps to minimize the potassium loss characteristically induced by the thiazide component.</p>
<p>The <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> of spironolactone is mediated through its action as a specific pharmacologic antagonist of aldosterone, primarily by competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Hydrochlorothiazide promotes the excretion of sodium and water primarily by inhibiting their reabsorption in the cortical diluting segment of the distal renal tubule.</p>
<p>Spironolactone and hydrochlorothiazide is effective in significantly lowering the systolic and diastolic blood pressure in many patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>, even when aldosterone secretion is within normal limits.</p>
<p>Both spironolactone and hydrochlorothiazide reduce exchangeable sodium, plasma volume, body weight, and blood pressure. The diuretic and antihypertensive effects of the individual components are potentiated when spironolactone and hydrochlorothiazide are given concurrently.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9e4d0759-c6d1-4c4f-8266-1964b22b67a6"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Spironolactone is rapidly and extensively metabolized. Sulfur-containing products are the predominant metabolites and are thought to be primarily responsible, together with spironolactone, for the therapeutic effects of the drug. The following pharmacokinetic data were obtained from 12 healthy volunteers following the administration of 100 mg of spironolactone (as tablets) daily for 15 days. On the 15th day, spironolactone was given immediately after a low fat breakfast and blood was drawn thereafter.</p>
<table width="100%">
<col width="26%">
<col width="24%">
<col width="24%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Accumulation Factor:</span><br><span class="Bold">AUC (0 to 24 hr, day 15)/AUC (0 to 24 hr, day 1)</span>
</th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Mean Peak Serum Concentration</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Mean (SD) Post-Steady State Half-Life</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="center"><p class="First">7-<span class="Italics">α</span>-(thiomethyl) spirolactone (TMS)</p></td>
<td class="Toprule" align="center"><p class="First">1.25</p></td>
<td class="Toprule" align="center"><p class="First">391 ng/mL at 3.2 hr</p></td>
<td class="Toprule" align="center"><p class="First">13.8 hr (6.4) (terminal)</p></td>
</tr>
<tr>
<td align="center"><p class="First">6-<span class="Italics">β</span>-hydroxy-7-<span class="Italics">α</span>-(thiomethyl) spirolactone (HTMS)</p></td>
<td align="center"><p class="First">1.50</p></td>
<td align="center"><p class="First">125 ng/mL at 5.1 hr</p></td>
<td align="center"><p class="First">15 hr (4) (terminal)</p></td>
</tr>
<tr>
<td align="center"><p class="First">Canrenone (C)<br></p></td>
<td align="center"><p class="First">1.41</p></td>
<td align="center"><p class="First">181 ng/mL at 4.3 hr</p></td>
<td align="center"><p class="First">16.5 hr (6.3) (terminal)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First">Spironolactone</p></td>
<td class="Botrule" align="center"><p class="First">1.30</p></td>
<td class="Botrule" align="center"><p class="First">80 ng/mL at 2.6 hr</p></td>
<td class="Botrule" align="center"><p class="First">Approximately 1.4 hr (0.5) (<span class="Italics">β</span> half-life)</p></td>
</tr>
</tbody>
</table>
<p>The pharmacological activity of spironolactone metabolites in man is not known. However, in the adrenalectomized rat the antimineralocorticoid activities of the metabolites C, TMS, and HTMS, relative to spironolactone, were 1.1, 1.28, and 0.32, respectively. Relative to spironolactone, their binding affinities to the aldosterone receptors in rat kidney slices were 0.19, 0.86, and 0.06, respectively.</p>
<p>In humans, the potencies of TMS and 7-α-thiospirolactone in reversing the effects of the synthetic mineralocorticoid, fludrocortisone, on urinary electrolyte composition were 0.33 and 0.26, respectively, relative to spironolactone. However, since the serum concentrations of these steroids were not determined, their incomplete absorption and/or first-pass metabolism could not be ruled out as a reason for their reduced <span class="Italics">in vivo</span> activities.</p>
<p>Spironolactone and its metabolites are more than 90% bound to plasma proteins. The metabolites are excreted primarily in the urine and secondarily in bile.</p>
<p>The effect of food on spironolactone absorption (two 100 mg spironolactone tablets) was assessed in a single-dose study of nine healthy, drug-free volunteers. Food increased the bioavailability of unmetabolized spironolactone by almost 100%. The clinical importance of this finding is not known.</p>
<p>Hydrochlorothiazide is rapidly absorbed following oral administration. Onset of action of hydrochlorothiazide is observed within one hour and persists for 6 to 12 hours. Hydrochlorothiazide plasma concentrations attain peak levels at 1 to 2 hours and decline with a half-life of 4 to 5 hours. Hydrochlorothiazide undergoes only slight metabolic alteration and is excreted in urine. It is distributed throughout the extracellular space, with essentially no tissue accumulation except in the kidney.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f54156e2-c125-4706-aeec-a5d001c5ff87"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a> section). Spironolactone and hydrochlorothiazide tablets, USP should be used only in those conditions described below. Unnecessary use of this drug should be avoided.</p>
<p>Spironolactone and hydrochlorothiazide tablets are indicated for:</p>
<p><span class="Bold">Edematous conditions </span>for patients with:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>:</span></p>
<dl>
<dt>•</dt>
<dd>For the management of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; </dd>
<dt>•</dt>
<dd>The treatment of diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> when other measures are considered inappropriate; </dd>
<dt>•</dt>
<dd>The treatment of patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> taking digitalis when other therapies are considered inadequate or inappropriate.</dd>
</dl>
<p><span class="Bold">Cirrhosis of the liver accompanied by <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and/or <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>:</span></p>
<dl>
<dt>•</dt>
<dd>Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium.</dd>
</dl>
<p><span class="Bold">The <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>:</span></p>
<dl>
<dt>•</dt>
<dd>For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.</dd>
</dl>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential hypertension</span>:</span></p>
<dl>
<dt>•</dt>
<dd>For patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> in whom other measures are considered inadequate or inappropriate; </dd>
<dt>•</dt>
<dd>In hypertensive patients for the treatment of a diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> when other measures are considered inappropriate;</dd>
<dt>•</dt>
<dd>Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. <p class="First">Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly.</p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2dbb6fc7-025c-4c37-9707-e091cded7f97"></a><a name="section-3.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes just as it is in the absence of pregnancy (however, see <a href="#i4i_pregnancy_id_pregnancy">PRECAUTIONS: Pregnancy</a>). <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b97d7e0a-79f1-4970-92bc-179d8dd95f36"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span>, significant impairment of renal excretory function, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, Addison’s disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. Spironolactone and hydrochlorothiazide may also be contraindicated in acute or severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Potassium supplementation, either in the form of medication or as a diet rich in potassium, should not ordinarily be given in association with spironolactone and hydrochlorothiazide therapy. Excessive potassium intake may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in patients receiving spironolactone and hydrochlorothiazide (see <a href="#i4i_precautions_general_id_general">PRECAUTIONS: General</a>). </p>
<p>Concomitant administration of spironolactone and hydrochlorothiazide with the following drugs or potassium sources may lead to severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>:</p>
<dl>
<dt>•</dt>
<dd>other potassium-sparing diuretics</dd>
<dt>•</dt>
<dd>ACE inhibitors </dd>
<dt>•</dt>
<dd>angiotensin II receptor antagonists </dd>
<dt>•</dt>
<dd>aldosterone blockers </dd>
<dt>•</dt>
<dd>non-steroidal anti-inflammatory drugs (NSAIDs), e.g., indomethacin </dd>
<dt>•</dt>
<dd>heparin and low molecular weight heparin</dd>
<dt>•</dt>
<dd> other drugs or conditions known to cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> </dd>
<dt>•</dt>
<dd>potassium supplements </dd>
<dt>•</dt>
<dd>diet rich in potassium </dd>
<dt>•</dt>
<dd>salt substitutes containing potassium </dd>
</dl>
<p>Spironolactone and hydrochlorothiazide should not be administered concurrently with other potassium-sparing diuretics. Spironolactone, when used with ACE inhibitors or indomethacin, even in the presence of a diuretic, has been associated with severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Extreme caution should be exercised when spironolactone and hydrochlorothiazide is given concomitantly with these drugs (see <a href="#i4i_interactions_id_drug">PRECAUTIONS: Drug Interactions</a>).</p>
<p>Spironolactone and hydrochlorothiazide should be used with caution in patients with impaired hepatic function because minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>Lithium generally should not be given with diuretics (see <a href="#i4i_interactions_id_drug">PRECAUTIONS: Drug Interactions</a>).</p>
<p>Thiazides should be used with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Thiazides may add to or potentiate the action of other antihypertensive drugs.</p>
<p>Sensitivity reactions to thiazides may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Sulfonamide derivatives, including thiazides, have been reported to exacerbate or activate <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d3d58e9-3092-4508-a44b-057738926ce9"></a><a name="section-5.1"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_general"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9519c27b-769c-42f7-88fb-4380a329d3fe"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Serum Electrolyte Abnormalities </span></span></h3>
<p class="First">Spironolactone can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. The risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be increased in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or with concomitant use of drugs that raise serum potassium (see <a href="#i4i_interactions_id_drug">Drug Interactions</a>). Hydrochlorothiazide can cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. The risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may be increased in patients with cirrhosis, brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, or with concomitant use of drugs that lower serum potassium. <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> can result in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> which appears difficult to treat despite potassium repletion. Monitor serum electrolytes periodically. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_719c6513-cc5a-4397-b9fe-54c644bfdba0"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Other Metabolic Disturbances</span></span></h3>
<p class="First">Hydrochlorothiazide may alter glucose tolerance and raise serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides. </p>
<p>Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and precipitate <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> in susceptible patients. </p>
<p>Hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium. Monitor calcium levels in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> receiving spironolactone and hydrochlorothiazide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f77f741-ed3c-4613-98d7-4471725355ac"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> may develop in association with the use of spironolactone; physicians should be alert to its possible onset. The development of <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> appears to be related to both dosage level and duration of therapy and is normally reversible when spironolactone and hydrochlorothiazide is discontinued. In rare instances, some <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span> may persist when spironolactone and hydrochlorothiazide is discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5b05180-3eb1-423b-a96a-3e0406cdc30f"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have been reported to occur in some patients. Caution is advised when driving or operating machinery until the response to initial treatment has been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_29a4e16f-2ef9-4d16-bc6e-348dc9b42b2e"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients who receive spironolactone and hydrochlorothiazide should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_3c5787d7-3037-4055-ba32-00b3e117a365"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be done at appropriate intervals, particularly in the elderly and those with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairments</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_drug"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ea1bead-2d3c-4d4d-8b1b-fdfe32d27d80"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">ACE Inhibitors, Angiotensin II Receptor Antagonists, Aldosterone Blockers, Potassium Supplements, Heparin, Low Molecular Weight Heparin, and Other Drugs Known to Cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></span></h3>
<p class="First">Concomitant administration may lead to severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3c35643-33e9-4d65-84e3-31b7527e5650"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Alcohol, Barbiturates or Narcotics</span></span></h3>
<p class="First">Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c53096a6-bbc9-427e-b132-b99de7952013"></a><a name="section-6.4.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Antidiabetic Drugs</span></span></h3>
<p class="First">(e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb327ff7-8694-45e3-9d98-91db59948492"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Corticosteroids, ACTH</span></span></h3>
<p class="First">Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1770cfe5-34e4-4e4e-8a41-060c70af6e4a"></a><a name="section-6.4.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pressor Amines (e.g., norepinephrine)</span></span></h3>
<p class="First">Both spironolactone and hydrochlorothiazide reduce the vascular responsiveness to norepinephrine. Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with spironolactone and hydrochlorothiazide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94ad72ec-90d3-48bb-9f02-43ff40513021"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Skeletal Muscle Relaxants, Nondepolarizing (e.g., tubocurarine)</span></span></h3>
<p class="First">Possible increased responsiveness to the muscle relaxant may result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b1e9504-6fdb-4627-abd3-98462a208000"></a><a name="section-6.4.7"></a><p></p>
<h3><span class="Bold"><span class="Italics">Lithium</span></span></h3>
<p class="First">Lithium generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7cc698c2-3829-4966-81ef-18841fed1c88"></a><a name="section-6.4.8"></a><p></p>
<h3><span class="Bold"><span class="Italics">Non-steroidal Anti-Inflammatory Drugs (NSAIDs)</span></span></h3>
<p class="First">In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. Combination of NSAIDs, e.g., indomethacin, with potassium-sparing diuretics has been associated with severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Therefore, when spironolactone and hydrochlorothiazide and NSAIDs are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9555411-2d67-4e42-97e4-31906aefc50b"></a><a name="section-6.4.9"></a><p></p>
<h3><span class="Bold"><span class="Italics">Digoxin</span></span></h3>
<p class="First">Spironolactone has been shown to increase the half-life of digoxin. This may result in increased serum digoxin levels and subsequent <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Monitor serum digoxin levels and adjust dose accordingly. Thiazide-induced <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, i.e. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>, which may lead to fatal arrhythmic events (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_76f1dfab-7b55-4664-b2ea-e825267a053b"></a><a name="section-6.4.10"></a><p></p>
<h3><span class="Bold"><span class="Italics">Cholestyramine</span></span></h3>
<p class="First">Hyperkalemic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> has been reported in patients given spironolactone concurrently with cholestyramine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_aa66e8f6-99d2-422a-8876-cf994b4a2192"></a><a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Thiazides should be discontinued before carrying out tests for parathyroid function (see <a href="#i4i_precautions_general_id_general">PRECAUTIONS: General</a>). Thiazides may also decrease serum PBI levels without evidence of alteration of thyroid function.</p>
<p>Several reports of possible interference with digoxin radioimmunoassays by spironolactone or its metabolites have appeared in the literature. Neither the extent nor the potential clinical significance of its interference (which may be assay specific) has been fully established.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e7f19141-47ce-4287-aee4-b456dba4f552"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4d388d8f-50ac-4d4a-b3cb-3f19f48221d8"></a><a name="section-6.6.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Spironolactone</span></span></h3>
<p class="First">Orally administered spironolactone has been shown to be a tumorigen in dietary administration studies performed in rats, with its proliferative effects manifested on endocrine organs and the liver. In an 18-month study using doses of about 50, 150, and 500 mg/kg/day, there were statistically significant increases in benign <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the thyroid and testes and, in male rats, a dose-related increase in proliferative changes in the liver (including hepatocytomegaly and hyperplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>). In a 24-month study in which the same <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat was administered doses of about 10, 30, and 100 mg spironolactone/kg/day, the range of proliferative effects included significant increases in <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and testicular interstitial cell tumors in males, and significant increases in thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas in both sexes. There was also a statistically significant, but not dose-related, increase in benign uterine endometrial stromal <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> in females.</p>
<p>A dose-related (above 30 mg/kg/day) incidence of <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myelocytic leukemia</span> was observed in rats fed daily doses of potassium canrenoate (a compound chemically similar to spironolactone and whose primary metabolite, canrenone, is also a major product of spironolactone in man) for a period of one year. In two year studies in the rat, oral administration of potassium canrenoate was associated with <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myelocytic leukemia</span> and hepatic, thyroid, testicular, and mammary tumors.</p>
<p>Neither spironolactone nor potassium canrenoate produced mutagenic effects in tests using bacteria or yeast. In the absence of metabolic activation, neither spironolactone nor potassium canrenoate has been shown to be mutagenic in mammalian tests <span class="Italics">in vitro</span>. In the presence of metabolic activation, spironolactone has been reported to be negative in some mammalian mutagenicity tests <span class="Italics">in vitro</span> and inconclusive (but slightly positive) for mutagenicity in other mammalian tests <span class="Italics">in vitro</span>. In the presence of metabolic activation, potassium canrenoate has been reported to test positive for mutagenicity in some mammalian tests <span class="Italics">in vitro</span>, inconclusive in others, and negative in still others.</p>
<p>In a three-litter reproduction study in which female rats received dietary doses of 15 and 500 mg spironolactone/kg/day, there were no effects on mating and fertility, but there was a small increase in incidence of stillborn pups at 500 mg/kg/day. When injected into female rats (100 mg/kg/day for 7 days, i.p.), spironolactone was found to increase the length of the estrous cycle by prolonging diestrus during treatment and inducing constant diestrus during a 2-week posttreatment observation period. These effects were associated with retarded ovarian follicle development and a reduction in circulating estrogen levels, which would be expected to impair mating, fertility, and fecundity. Spironolactone (100 mg/kg/day), administered i.p. to female mice during a 2-week cohabitation period with untreated males, decreased the number of mated mice that conceived (effect shown to be caused by an inhibition of ovulation) and decreased the number of implanted embryos in those that became pregnant (effect shown to be caused by an inhibition of implantation), and at 200 mg/kg, also increased the latency period to mating.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b249e025-a138-41a3-a61b-e89878113820"></a><a name="section-6.6.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></h3>
<p class="First">Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic in <span class="Italics">in vitro</span> assays using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (Ames assay) and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in <span class="Italics">in vivo</span> assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the <span class="Italics">Drosophila</span> sex-linked recessive lethal trait gene. Positive test results were obtained only in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 µg/mL, and in the <span class="Italics">Aspergillus nidulans</span> non-disjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_pregnancy"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_9d260538-a563-4c1a-a5e6-a6223d097950"></a><a name="section-6.7.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects. Pregnancy Category C</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_21d3ef1b-58cd-4c72-9a29-a06cf6b3eed2"></a><a name="section-6.7.1.1"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg hydrochlorothiazide/kg, respectively, provided no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3fcb6e8d-164d-4e4f-b50a-65d222bdba8e"></a><a name="section-6.7.1.2"></a><p></p>
<h4>Spironolactone</h4>
<p class="First">Teratology studies with spironolactone have been carried out in mice and rabbits at doses of up to 20 mg/kg/day. On a body surface area basis, this dose in the mouse is substantially below the maximum recommended human dose and, in the rabbit, approximates the maximum recommended human dose. No teratogenic or other embryotoxic effects were observed in mice, but the 20 mg/kg dose caused an increased rate of resorption and a lower number of live fetuses in rabbits. Because of its antiandrogenic activity and the requirement of testosterone for male morphogenesis, spironolactone may have the potential for adversely affecting sex differentiation of the male during embryogenesis. When administered to rats at 200 mg/kg/day between gestation days 13 and 21 (late embryogenesis and fetal development), <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of male fetuses was observed. Offspring exposed during late pregnancy to 50 and 100 mg/kg/day doses of spironolactone exhibited changes in the reproductive tract including dose-dependent decreases in weights of the ventral prostate and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> in males, ovaries and uteri that were enlarged in females, and other indications of endocrine dysfunction, that persisted into adulthood. There are no adequate and well-controlled studies with spironolactone in pregnant women. Spironolactone has known endocrine effects in animals including progestational and antiandrogenic effects. The antiandrogenic effects can result in apparent estrogenic side effects in humans, such as <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. Therefore, the use of spironolactone and hydrochlorothiazide in pregnant women requires that the anticipated benefit be weighed against the possible hazards to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_4edff5b8-1f4e-4cda-915d-938256b61c34"></a><a name="section-6.7.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Non-Teratogenic Effects</span></span></h3>
<p class="First">Spironolactone or its metabolites may, and hydrochlorothiazide does, cross the placental barrier and appear in cord blood. Therefore, the use of spironolactone and hydrochlorothiazide in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. The hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4d30c5ee-bc81-4540-bf62-fbad4dad2e59"></a><a name="section-6.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Canrenone, a major (and active) metabolite of spironolactone, appears in human breast milk. Because spironolactone has been found to be tumorigenic in rats, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. If use of the drug is deemed essential, an alternative method of infant feeding should be instituted.</p>
<p>Thiazides are excreted in human milk in small amounts. Thiazides when given at high doses can cause intense <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> which can in turn inhibit milk production. The use of spironolactone and hydrochlorothiazide during breast feeding is not recommended. If spironolactone and hydrochlorothiazide is used during breast feeding, doses should be kept as low as possible.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_35be7b03-f97f-4b00-9277-0a745a555bfa"></a><a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f333c7b8-25e8-411b-b277-d2791a2e8571"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported and, within each category (body system), are listed in order of decreasing severity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74596c3b-0dd1-4810-b8b4-44c49adf64c6"></a><a name="section-7.1"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First"><span class="Bold"><span class="Italics">Body as a whole:</span></span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (may be aggravated by alcohol, barbiturates, narcotics, or antihypertensive drugs).</p>
<p><span class="Bold"><span class="Italics">Digestive:</span></span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialoadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>:</span> acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span></span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, necrotizing angitis (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Bold"><span class="Italics">Metabolic:</span></span> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal:</span></span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous System/Psychiatric:</span></span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</p>
<p><span class="Bold"><span class="Italics">Renal:</span></span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
<p><span class="Bold"><span class="Italics">Skin:</span></span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> Transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ae007eab-7175-4dc6-936a-0c6e9595152c"></a><a name="section-7.2"></a><p></p>
<h2>Spironolactone</h2>
<p class="First"><span class="Bold"><span class="Italics">Digestive:</span></span> <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">Gastric bleeding</span>, ulceration, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and cramping, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold"><span class="Italics">Reproductive:</span></span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> (see <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a>), inability to achieve or maintain erection, irregular menses or <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="195321" conceptname="Postmenopausal bleeding">postmenopausal bleeding</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>. Carcinoma of the breast has been reported in patients taking spironolactone but a cause and effect relationship has not been established.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span></span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, maculopapular or erythematous cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Italics"><span class="Bold">Metabolism:</span></span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a> and <a href="#i4i_precautions_id_precautions">PRECAUTIONS</a><span class="Italics">).</span></p>
<p><span class="Italics"><span class="Bold">Musculoskeletal:</span></span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous System/Psychiatric:</span></span> <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.</p>
<p><span class="Bold"><span class="Italics">Liver/Biliary:</span></span> A very few cases of mixed cholestatic/hepatocellular toxicity, with one reported fatality, have been reported with spironolactone administration.</p>
<p><span class="Bold"><span class="Italics">Renal:</span></span> Renal dysfunction (including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>).</p>
<p><span class="Bold"><span class="Italics">Skin:</span></span> <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.<span class="Bold">  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_fdd8449c-cab5-416f-98b2-8716a3ae083b"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The oral LD<span class="Sub">50</span> of spironolactone is greater than 1,000 mg/kg in mice, rats, and rabbits. The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.</p>
<p>Acute overdosage of spironolactone may be manifested by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, maculopapular or erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Rarely, instances of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (less commonly seen with spironolactone and hydrochlorothiazide because the hydrochlorothiazide component tends to produce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>), or <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> may occur in patients with severe liver disease, but these are unlikely due to acute overdosage.</p>
<p>However, because spironolactone and hydrochlorothiazide tablets contain both spironolactone and hydrochlorothiazide, the toxic effects may be intensified, and signs of thiazide overdosage may be present. These include <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> such as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. The potassium-sparing action of spironolactone may predominate and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may occur, especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. BUN determinations have been reported to rise transiently with hydrochlorothiazide. There may be <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or even <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52a0a31f-4224-4543-8453-b78b467cc188"></a><a name="section-8.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or evacuate the stomach by lavage. There is no specific antidote. Treatment is supportive to maintain hydration, electrolyte balance, and vital functions.</p>
<p>Patients who have <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may develop spironolactone-induced <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. In such cases, spironolactone and hydrochlorothiazide should be discontinued immediately. With severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, the clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> solution, and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. These are temporary measures to be repeated as required. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. Persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may require dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_83d7de9d-59ac-49e9-918f-f6d77d69b7e2"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Optimal dosage should be established by individual titration of the components (see <a href="#box">BOXED WARNING</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2321aeb6-6edc-4d11-96dd-866160fb1f55"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> in Adults (<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">Hepatic Cirrhosis</span> or <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span>)</h2>
<p class="First">The usual maintenance dose of spironolactone and hydrochlorothiazide tablets is 100 mg each of spironolactone and hydrochlorothiazide daily, administered in a single dose or in divided doses, but may range from 25 mg to 200 mg of each component daily depending on the response to the initial titration. In some instances it may be desirable to administer separate tablets of either spironolactone or hydrochlorothiazide in addition to spironolactone and hydrochlorothiazide tablets in order to provide optimal individual therapy.</p>
<p>The onset of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> with spironolactone and hydrochlorothiazide tablets occurs promptly and, due to prolonged effect of the spironolactone component, persists for 2 to 3 days after spironolactone and hydrochlorothiazide tablets are discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_398ea758-9383-4ccf-8b78-e5a7721cdfb8"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential Hypertension</span></h2>
<p class="First">Although the dosage will vary depending on the results of titration of the individual ingredients, many patients will be found to have an optimal response to 50 mg to 100 mg each of spironolactone and hydrochlorothiazide daily, given in a single dose or in divided doses.</p>
<p>Concurrent potassium supplementation is not recommended when spironolactone and hydrochlorothiazide tablets are used in the long-term management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or in the treatment of most edematous conditions, since the spironolactone content of spironolactone and hydrochlorothiazide tablets is usually sufficient to minimize loss induced by the hydrochlorothiazide component.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_de8d5337-8a79-4922-a528-608396ff600a"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Spironolactone and Hydrochlorothiazide Tablets, USP are available containing 25 mg of spironolactone, USP and 25 mg of hydrochlorothiazide, USP.</p>
<p>The tablets are ivory round, tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">41</span> below the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 0378-0141-01<br>bottles of 100 tablets</p>
<p>NDC 0378-0141-05<br>bottles of 500 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>REVISED MAY 2015<br>SPHZ:R18</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d984eddc-1d7e-4475-acc0-44dc77803de5"></a><a name="section-11"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg/ 25 mg</span></p>
<p><span class="Bold">NDC 0378-0141-01</span></p>
<p><span class="Bold">Spironolactone</span><br><span class="Bold">and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">25 mg/</span><br><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx only 100 Tablets</span></p>
<p>Each tablet contains:<br>Spironolactone, USP 25 mg<br>Hydrochlorothiazide, USP 25 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0141A14</span></p>
<div class="Figure">
<a name="id892"></a><img alt=" Spironolactone and Hydrochlorothiazide Tablets 25 mg/25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66134130-5718-483b-a076-36ecdb0add34&amp;name=25869be1-c481-4e3a-9fee-1505c41b39d1-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">spironolactone and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0141</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SPIRONOLACTONE</strong> (SPIRONOLACTONE) </td>
<td class="formItem">SPIRONOLACTONE</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MENTHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PEPPERMINT OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (Ivory) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;41</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0141-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-0141-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA086513</td>
<td class="formItem">07/26/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>95e5759a-8817-49a6-be03-2686a08a00de</div>
<div>Set id: 66134130-5718-483b-a076-36ecdb0add34</div>
<div>Version: 4</div>
<div>Effective Time: 20150507</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
